Addex Therapeutics Shares Plunge Premarket on Epilepsy Study Failure
By Colin Kellaher
U.S.-listed shares Addex Therapeutics plunged nearly 60% in premarket trading Monday after the clinical-stage biopharmaceutical company reported the failure of a mid-stage study of a proposed epilepsy drug it is developing with Johnson & Johnson.
Addex said the Phase 2 study evaluating adjunctive ADX71149 administration in patients with focal onset seizures with suboptimal response to levetiracetam or brivaracetam missed its primary endpoint of time for patients to reach baseline seizure count.
Geneva-based Addex said it is still analyzing the study data, adding that it will provide more details when the analysis is complete and will work with J&J to determine the next steps for the ADX71149 program.
J&J's Janssen unit had been conducting the Phase 2 study since June 2021 under a worldwide research collaboration and license agreement and is responsible for financing the development and commercialization, if any, of ADX71149.
Addex is eligible for up to about $117 million in success-based development and regulatory milestone payments under the agreement, along with royalties on product sales.
Addex's U.S.-listed shares, which closed Friday at $16.10, were recently down 58% to $6.81 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 29, 2024 07:37 ET (11:37 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing
-
Going Into Earnings, Is Nvidia Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Arista Stock a Buy, a Sell, or Fairly Valued?
-
A Cheap Dividend Aristocrat to Buy Before It Bounces Back
-
Alibaba Earnings: More Positive Outlook Despite Mixed Results
-
After Earnings and a 56% Rally In 2024, Is Arm Stock a Buy, a Sell, or Fairly Valued?
-
How Morningstar Rates Stocks